Abstract 3270
Background
Symptoms of anxiety and depression are common in patients with cancer, and associated with impaired quality of life (QoL). The aim was to evaluate the effect of internet-based stepped care (iCAN-DO) on symptoms of anxiety and depression and QoL in patients with cancer, compared to standard care (SC).
Methods
iCAN-DO was developed in cooperation between professionals and patients with cancer. Consecutive patients (N = 245), with self-reported symptoms of anxiety and/or depression, according to the Hospital Anxiety and Depression Scale, were randomized to iCAN-DO or SC. iCAN-DO comprised interactive support, including psycho-education and self-care strategies (Step 1), and cognitive behavioural therapy (Step 2) for those with persistent symptoms 1, 4 and/or 7 months post randomization. Data was collected before randomization and at 1, 4, 7 and 10 months post randomization.
Results
One-hundred and five of 124 patients (85%) used iCAN-DO to some extent and 49% completed the 10 months assessment. Patients randomized to iCAN-DO reported lower levels of symptoms of depression (mean 7.3 vs 6.2), and a clinically significant decrease of depression from baseline to 10 months (decrease 23% vs 8%), compared to standard care (p < 0.05). In addition, the proportion of patients with clinical depression was smaller in iCAN-DO (15% vs 23%) compared to SC, at 10 months (p < 0.05). There was now difference between iCAN-DO and SC with regard to symptoms of anxiety and QoL.
Conclusions
Internet-based stepped care for patients with cancer who self-report symptoms of anxiety and/or depression is effective to decrease depression, for some patients. Further studies are needed to develop internet-based support to suit different needs, and competence to use information technologies.
Clinical trial identification
NCT01630681.
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University Psychosocial Care Programme.
Funding
Swedish government, Forte Research Council, Swedish Cancer Society, Uppsala County Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract